PRFX PRESS-RELEASE SEC Filing Analysis

Latest settled — T+5d

PRFX ▼ -3.43% at T+5d

NEUTRAL call ✗ call lost -3.43% · α vs SPY -5.12% · entry $2.04 → $1.97

Next anchor: T+20d in 7d

Currently $1.61 · -21.08% from $2.04 entry

Entry anchored
Apr 28, 07:59 AM ET
via Databento tick

T+1d

-7.84%

call -7.84% · α -7.83%

$1.88

settled 21d ago

T+5d

-3.43%

call -3.43% · α -5.12%

$1.97

settled 15d ago

T+20d

—

call — · α —

—

in 7d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

PRF Technologies announced FDA clearance of its IND application for OcuRing™-K, a sustained-release intraocular ring for post-cataract surgery pain and inflammation, enabling a Phase II trial expected to begin enrollment in H2 2026. This is an early-stage regulatory milestone for a pre-revenue micro-cap with no approved products and a going concern risk, providing limited near-term commercial value.

Actionable Insight

IND clearance is a positive de-risking step but does not change the company's pre-revenue, going-concern status. Monitor for Phase II enrollment updates and any capital raise announcements, as the company will likely need additional funding to advance the trial.

Key Facts

FDA cleared IND for OcuRing™-K, a bio-erodible intraocular ring delivering ketorolac for cataract surgery pain/inflammation.
Phase II multi-center trial planned in the U.S., with patient enrollment expected to begin in H2 2026.
PRF has a $2M market cap, no approved products, and a going concern risk as noted in forward-looking statements.
OcuRing™-K is developed through majority-owned subsidiary LayerBio, Inc.

Financial Impact

No financial figures disclosed; pre-revenue clinical-stage company with $2M market cap.

r&d_expensescash_burn

Risk Factors

Going concern risk: PRF has a history of losses and may need to raise capital, diluting existing shareholders.
Phase II trial may fail to meet endpoints, delaying or ending the program.
Micro-cap with low liquidity and high volatility; stock may not react significantly to early-stage regulatory milestones.

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

0% bullish (6 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3282536

4 reports for PRFX

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for PRFX — sortable, filterable
	Type				Now
May 7, 2026 13d ago	6-K BEARISH ★ 7/10	$1.94 $1.58	▲ +18.56%	▲ +20.02%	$1.61 (+17.01%)
Apr 28, 2026 22d ago	Press Release NEUTRAL ★ 4/10	$2.04 $1.97	▼ −3.43%	▼ −5.12%	$1.61 (−21.08%)
Mar 27, 2026 7w ago	6-K MIXED ★ 6/10	$2.08 $2.53	▲ +21.63%	▲ +17.77%	$1.61 (−22.60%)
Mar 26, 2026 7w ago	20-F BEARISH ★ 6/10	$2.08 $2.53	▼ −21.63%	▼ −17.77%	$1.61 (+22.60%)

US Market Status

Market Closed — Opens Thu (< 1m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access